Esperion to Participate in Upcoming Investor Conferences
November 08, 2018 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results
November 01, 2018 16:05 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program of Bempedoic Acid and Positive Cumulative Results
October 28, 2018 17:10 ET
|
Esperion Therapeutics, Inc.
– Phase 3 Program Achieved Safety and Tolerability Objectives –– Bempedoic Acid Achieved Additional 18% to 31% LDL-C Lowering in Patients on Maximally Tolerated Statins and Provided Additional 19% to...
Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid
October 28, 2018 17:00 ET
|
Esperion Therapeutics, Inc.
– Study Met Safety and Tolerability Endpoints in 52-Week Study –– Bempedoic Acid Achieved Additional 18% LDL-C Lowering in Patients on Maximally Tolerated Statins and Provided Additional 19% hsCRP...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 18, 2018 17:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2018 Financial Results
August 02, 2018 07:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc. (ESPR) and Encourages Investors to Contact the Firm
July 05, 2018 17:23 ET
|
Bragar Eagel & Squire
NEW YORK, July 05, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of...
Esperion to Host Analyst and Investor Day Event on July 10
July 03, 2018 08:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 03, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Announces Late-Breaking Oral Presentation of Full Study 4 Results (1002-048) at the International Symposium on Atherosclerosis
June 12, 2018 16:01 ET
|
Esperion Therapeutics, Inc.
– Simultaneous Presentation of Full Data from 1st Phase 3 Study at ISA and Publication in the Journal Atherosclerosis – ANN ARBOR, Mich., June 12, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR)...
Esperion to Participate in Fireside Chat at the Jefferies 2018 Global Healthcare Conference
May 30, 2018 09:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 30, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...